September 20, 2026 2:02 PM ET
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX.
Zii
NASDAQ:JAZZ